Virtual Incision Corporation has received U.S. Food and Drug Administration 510(k) clearance to use its MIRA Surgical System in benign hysterectomy procedures, expanding the miniaturized robotic-assisted surgery platform beyond its original colectomy indication and into one of the largest categories of soft-tissue surgery. The company said the expanded indication was supported by a prospective investigational-device study involving five surgeons at three U.S. hospitals.
The clearance matters because MIRA challenges one of the assumptions that has shaped robotic surgery for decades: that sophisticated robotic assistance requires a large mainframe system occupying substantial operating-room space. Virtual Incision says MIRA’s patient-side device weighs approximately two pounds, or less than one kilogram, and can be deployed without a dedicated robotic operating room, docking infrastructure or permanent mainframe installation.
What did the FDA clear MIRA to do in gynecologic surgery?
The new indication covers benign hysterectomy procedures. Virtual Incision said more than one million women in the United States undergo surgery for benign gynecologic conditions annually, creating a substantially larger addressable procedure base than MIRA’s initial use in colectomy.
The clearance builds on MIRA’s February 2024 De Novo authorization for adults undergoing colectomy. That authorization established the platform as a new type of miniaturized robotic-assisted surgery device, while the subsequent 510(k) pathway allows Virtual Incision to expand its permitted use as supporting evidence develops.
The hysterectomy clearance was supported by a prospective clinical investigation involving five surgeons at three U.S. hospitals. The company said the study confirmed the system’s safety and performance for benign hysterectomy, although the announcement did not provide a complete numerical breakdown of operative times, conversion rates, complications or other study endpoints.
That absence means the regulatory milestone is clear while the clinical-performance comparison with larger robotic systems remains less fully visible to the public. Peer-reviewed publication of detailed results would therefore help hospitals evaluate where MIRA fits within existing gynecologic workflows.
How can a two-pound robot perform minimally invasive surgery?
MIRA takes a very different engineering approach from conventional multi-arm robotic platforms. Instead of surrounding the patient with large externally mounted robotic arms, the miniature system introduces articulated components through the surgical access point and creates triangulation internally.
Virtual Incision says the system incorporates shoulders, arms and continuous wrist rotation inside the body, giving surgeons the ability to grasp, retract and dissect tissue while maintaining the compact external footprint. The device is designed to be drape- and dock-free and can be moved between operating rooms rather than permanently assigning a theatre to robotic surgery.
That architecture could matter because the capital cost of a surgical robot is only part of the adoption equation. Hospitals must also consider room utilization, turnover time, storage, maintenance, staff training and whether a large robotic platform can generate enough procedure volume to justify occupying valuable operating-room infrastructure.
A smaller platform could alter that calculation, particularly for ambulatory surgery centers, community hospitals and facilities where traditional robotic infrastructure has been difficult to justify.
Could miniature surgical robots broaden access to robotic-assisted surgery?
That is the central proposition behind miniaturized robotic-assisted surgery. Large tertiary hospitals can support expensive surgical platforms because they perform high numbers of robotic procedures across urology, gynecology, general surgery and other specialties. Smaller facilities may have fewer cases, less physical space and tighter capital budgets.
A portable robot potentially allows those institutions to access robotic assistance without redesigning a theatre around a permanent mainframe. Virtual Incision also positions MIRA as a complementary device for hospitals that already operate larger systems, potentially adding robotic capacity without purchasing another full-scale installation.
The commercial outcome will depend on factors that regulatory clearance alone does not answer. Hospitals will need to compare acquisition and disposable costs, procedure efficiency, surgeon learning curves, clinical outcomes, instrument range and service support with both conventional laparoscopy and established robotic systems.
Miniaturization can reduce infrastructure, but it can also create engineering constraints. Larger robotic systems have benefited from decades of refinement, broad instrument libraries, advanced imaging integration and deeply embedded surgeon training. Smaller competitors must prove that portability does not come at the expense of capability.
Why is hysterectomy strategically important for MIRA?
Hysterectomy represents a large and established minimally invasive surgical market where laparoscopy and robotic assistance are already familiar. That makes the new indication strategically different from introducing an entirely new procedure type.
Virtual Incision does not need to persuade gynecologic surgeons that minimally invasive surgery has value. Instead, it must demonstrate why a miniaturized robot improves the logistics or economics of delivering that approach.
The procedure category also allows the company to test its thesis across a much broader network of facilities. Benign gynecologic surgery occurs in academic hospitals, community institutions and ambulatory environments, exactly the range of sites where a smaller robotic platform could potentially differentiate itself.
Virtual Incision has not yet announced broad commercial timing for the gynecology indication. The company said MIRA is currently commercially available in the United States for colectomy and that introduction into gynecologic surgery will follow as part of a staged expansion strategy.
Could the future robotic operating room contain several different robots?
The traditional model has tended toward one large general-purpose platform designed to support many surgical specialties. Miniaturized systems create the possibility of a more fragmented market in which hospitals choose different robotic architectures for different procedures.
That could resemble other medical-device sectors, where facilities use a portfolio of specialized systems rather than expecting one machine to perform every function. A hospital might eventually use a large multi-port robot for highly complex surgery, a miniature device for high-volume routine soft-tissue procedures and entirely different platforms for orthopedics, endoscopy or endovascular intervention.
Such fragmentation would increase competition but could also place new demands on training and procurement. Surgeons and operating-room teams would need to become comfortable switching between interfaces and instrument ecosystems.
MIRA’s hysterectomy clearance therefore represents more than an additional line on a device label. It tests whether robotic-assisted surgery can move away from a mainframe-centered model toward portable, procedure-scaled robotics that can follow the patient and surgeon rather than forcing every case into a specialized robotic room.